Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Martin Pule Insider Profile
4 Followers
Martin Pule, Chief Scientific Officer at Autolus Therapeutics, holds ― shares in Autolus Therapeutics (Ticker: AUTL). Most recently, Martin Pule Sold $698,741 shares of Autolus Therapeutics on Sep 17, 2024 for an estimated value of 2.96M.
Martin Pule has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Martin Pule does not currently own shares as a corporate insider.
A breakdown of Martin Pule's holdings
Insider Roles
Chief Scientific Officer
Roles that Martin Pule holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Martin Pule
Martin Pule's Trading History
List of latest transactions for each holding click on a transaction to see Martin Pule's performance on stock
You May Also Like
Martin Pule insider profile FAQ
What is the percentage of profitable transactions made by Martin Pule?
The percentage of profitable transactions made by Martin Pule is ―.
What is the average return per transaction made by Martin Pule?
The average return per transaction made by Martin Pule is ―.
What stocks does Martin Pule hold?
Martin Pule holds: AUTL stocks.
What was Martin Pule’s latest transaction?
Martin Pule latest transaction was an Informative Sell of $2.96M.
What was Martin Pule's most profitable transaction?
Martin Pule’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Martin Pule's role in Autolus Therapeutics?
Martin Pule's role in Autolus Therapeutics is Chief Scientific Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.